Back to Search
FRANCIS MAH, MD
MD
Specialist
NPI: 1528032620IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MD069140L(PA)
Education
UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE
Class of 1995
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
PMID 18167176·Curr Med Res Opin·2008
2-rct
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
PMID 17559743·Curr Med Res Opin·2007
2-rct
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
PMID 17525656·Cornea·2007
4-observational
Role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis in experimental in vivo studies.
PMID 16565003·J Cataract Refract Surg·2006
7-preclinical
Bacterial conjunctivitis in pediatrics and primary care.
PMID 16898650·Pediatr Clin North Am·2006
6-review
Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.
PMID 15232471·Curr Opin Ophthalmol·2004
6-review
Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects.
PMID 19630694·Expert Opin Drug Metab Toxicol·2009
6-review
Antibiotic susceptibility of conjunctival bacterial isolates from refractive surgery patients.
PMID 19395038·Ophthalmology·2009
4-observational
Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model.
PMID 18370872·J Ocul Pharmacol Ther·2008
7-preclinical
Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis.
PMID 18665809·J Ocul Pharmacol Ther·2008
4-observational
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
PMID 18085465·Curr Eye Res·2007
4-observational
Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.
PMID 17889778·J Cataract Refract Surg·2007
6-review
The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy.
PMID 16978577·Am J Ophthalmol·2006
8-other
An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
PMID 16183128·Ophthalmology·2005
8-other
Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
PMID 16083841·Am J Ophthalmol·2005
7-preclinical
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
PMID 15860293·Am J Ophthalmol·2005
7-preclinical
Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
PMID 15234279·Am J Ophthalmol·2004
7-preclinical
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
PMID 15289131·Am J Ophthalmol·2004
4-observational
The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models.
PMID 12828841·J Ocul Pharmacol Ther·2003
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 203 LOTHROP ST
PITTSBURGH, PA 15213 - Phone
- (412) 647-2200
Quick Facts
- NPI
- 1528032620
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile